The past decade has seen a rise in the proportion of infants who have been exposed to opioid drugs, such as heroin or prescription pain relievers (e.g., oxycodone, hydrocodone), at birth.1 Between 2000 and 2009, opioid use among women who gave birth increased in the United States from 1.19 to 5.63 per 1,000 hospital births per year.1 A tandem increase has been seen in the incidence of neonatal abstinence syndrome (NAS) among newborns—a neonatal drug withdrawal syndrome primarily caused by maternal opioid use—during the same period (from 1.20 per 1,000 hospital births per year in 2000 to 3.39 per 1,000 hospital births per year in 2009).1
Dependence on opioids during pregnancy is associated with an increased risk of adverse outcomes for infants and mothers. The incidence of NAS in newborns born to opioid-dependent women is between 70 and 95 percent.2 Research suggests that newborns with NAS (most commonly in the context of opioid misuse during pregnancy, although other drugs have also been implicated) are more likely than all other hospital births to have low birthweight or respiratory complications.1 Untreated heroin and other opioid misuse during pregnancy is also associated with increased risk of placental abruption, preterm labor, maternal obstetric complications, and fetal death.2,3,4
The standard treatment for opioid use disorder during pregnancy is methadone or buprenorphine maintenance therapy.2,3,4,5,6 Exposure to methadone or buprenorphine in utero can result in NAS; however, using these substances among pregnant women with opioid use disorder improves outcomes for mothers and infants compared with the outcomes for mothers and infants who receive no treatment.2,3,4,5,6 Maintenance therapy with methadone or buprenorphine provides a steady concentration of opioids in the pregnant woman's blood, preventing the fetus from repeatedly experiencing cycles of opioid toxicity and withdrawal.2,6 Pregnant women who receive maintenance therapy with methadone or buprenorphine often require comprehensive medical treatment, including routine prenatal care.2,6 For example, research has shown that pregnant women admitted to substance use treatment for opioid misuse often need referrals to routine prenatal medical care.2,6
This issue of The CBHSQ Report includes data from the National Survey on Drug Use and Health (NSDUH), the Treatment Episode Data Set (TEDS), and the National Survey of Substance Abuse Treatment Services (N-SSATS) to examine opioid misuse and treatment among women of childbearing age. NSDUH data provide information on opioid misuse among women of childbearing age in the general population, whereas TEDS data focus on women of childbearing age who have been admitted to substance use treatment for opioid misuse. N-SSATS data describe specialized, relevant services offered to women within the nation's substance use treatment facilities.
NSDUH is an annual survey of the U.S. civilian, noninstitutionalized population aged 12 years or older. In the NSDUH section of this report, opioid misuse is defined as use of heroin or nonmedical use of prescription-type pain relievers in the past month.7,8 Combined data from the 2007 to 2012 NSDUHs are used to estimate opioid misuse among women aged 15 to 44 who reported that they were pregnant at the time of the interview. Comparisons are made with those who were not pregnant (referred to as "nonpregnant women" in the NSDUH section of this report). NSDUH data from 2007 to 2012 were combined to ensure that there were adequate numbers of pregnant women (including pregnant women who were users of opioids) to generate reliable estimates. In the combined 2007 to 2012 NSDUH data, about 145,000 females were aged 15 to 44. Because NSDUH data were combined from multiple years, however, the estimates that are presented in this report represent annual averages.
TEDS is a national data system that contains information on people aged 12 years or older who were admitted to substance use treatment facilities annually. State substance use agencies report the data to the Substance Abuse and Mental Health Services Administration. Treatment programs receiving any public funds are requested to provide TEDS data on publicly and privately funded clients. TEDS collects information on up to three substances of misuse that led to the treatment episode. In this report, TEDS data are used to examine the characteristics of admissions aged 15 to 44 who were pregnant at the time of treatment entry, including the type of opioid misuse, whether the use of methadone or buprenorphine was a part of the treatment plan,9,10 and health insurance status. Comparisons are made with female admissions aged 15 to 44 who were not pregnant at the time of admission (referred to as "nonpregnant female admissions"). Notably, TEDS records represent admissions rather than individuals because a person may be admitted to treatment more than once.
N-SSATS is an annual survey of all known substance use treatment facilities, both public and private. In this report, N-SSATS data are used to describe substance use treatment facilities that offer special programs or groups for pregnant/postpartum women, including treatment setting,11 operation of an opioid treatment program (OTP),9,12,13 opioid detoxification services offered, child care services offered, and whether facilities accepted Medicaid. When applicable, comparisons are made with those facilities that did not offer specially designed programs or groups to pregnant/postpartum women.
For NSDUH, the observed difference between estimates is evaluated in terms of statistical significance. Statistical significance is based on the p value of the test statistic and refers to the probability that a difference as large as that observed would occur due to random variability in the estimates if there were no differences in the percentages being compared. In this report, the significance of observed differences is reported at the .05 level when the p value is defined as less than or equal to the designated significance level. Because TEDS and N-SSATS both involve censuses and actual counts rather than estimates, statistical significance and confidence intervals are not applicable. For these two datasets, the differences between subgroups mentioned in the text of this report have Cohen's h effect size greater than or equal to 0.20, indicating that they are considered to be meaningful.
Past Month Opioid Misuse
Combined data from the 2007 to 2012 NSDUHs indicate that an annual average of about 21,000 pregnant women aged 15 to 44 misused opioids in the past month. The percentage of women misusing opioids in the past month was lower among pregnant women aged 15 to 44 than among nonpregnant women in that age range (0.9 vs. 2.6 percent).
To better understand the differences and similarities in opioid misuse among women aged 15 to 44 by their pregnancy status, comparisons were made between pregnant and nonpregnant women in age subgroups. Past month opioid misuse was lower among pregnant women aged 18 to 25 than among same-aged nonpregnant women (1.5 vs. 3.9 percent) (Figure 1). Similarly, past month opioid misuse was lower among pregnant women aged 26 to 34 than among same-aged nonpregnant women (0.5 vs. 2.3 percent).
Figure 1. Past month opioid misuse among women aged 15 to 44, by pregnancy status and age: 2007 to 2012
Making comparisons between pregnant and nonpregnant women of varying age groups provides an opportunity to determine whether opioid misuse differs by pregnancy status in the same way across different age groups (e.g., among women aged 18 to 25, are pregnant women more or less likely to misuse opioids than nonpregnant women?). Another way of understanding opioid misuse among pregnant women is to see whether age-related patterns (e.g., higher misuse by younger women) occur regardless of pregnancy status. Nonpregnant women aged 18 to 25 (3.9 percent) and nonpregnant women aged 15 to 17 (3.6 percent) were more likely to misuse opioids in the past month than nonpregnant women aged 26 to 34 (2.3 percent) and nonpregnant women aged 35 to 44 (1.6 percent). Similarly, among pregnant women, those aged 15 to 17 and 18 to 25 were more likely to misuse opioids in the past month than pregnant women aged 26 to 34 (2.8 and 1.5 percent vs. 0.5 percent). The estimate of opioid misuse for pregnant women aged 35 to 44 was suppressed because of low precision.
In addition to identifying whether there is a relationship among age, pregnancy status, and opioid misuse, comparisons were also made by poverty status (i.e., whether the respondent was living at or above the federal poverty level or below it). Past month opioid misuse was less common for pregnant women living below the federal poverty level than for nonpregnant women living below the federal poverty level (1.6 vs. 3.4 percent); misuse was also less common for pregnant women living at or above the federal poverty level than for nonpregnant women living at or above the federal poverty level (0.7 vs. 2.5 percent) (Figure 2). When looking at differences among pregnant women by their poverty status, pregnant women who were living below the federal poverty level were more likely than pregnant women living at or above the federal poverty level to be past month opioid misusers (1.6 vs. 0.7 percent; Figure 2). This pattern was also true for nonpregnant women aged 15 to 44: those living below the federal poverty level were more likely than nonpregnant women living at or above the federal poverty level to be past month opioid misusers (3.4 vs. 2.5 percent; Figure 2).
Figure 2. Past month opioid misuse among women aged 15 to 44, by pregnancy status and federal poverty level: 2007 to 2012
Opioid Misuse by Pregnancy Trimester
NSDUH also collects data on the number of months that women are pregnant. This information can be then used to examine past month opioid misuse among pregnant women according to the trimester of their pregnancies. Pregnant women who were in their first trimester (i.e., 1 to 3 months) at the time of the interview were more likely than women in their second and third trimesters (i.e., 4 to 6 months and 7 to 9 months, respectively) at the time of the interview to have misused opioids in the past month. Specifically, 1.6 percent of pregnant women in their first trimester misused opioids in the past month, compared with 0.7 percent of those in their second trimester and 0.3 percent of those in their third trimester (Figure 3).
Opioid Misuse by Presence of Other Children in the Household
The presence of other children aged 5 years or younger in the household can also be determined with NSDUH data. Pregnant women aged 15 to 44 who had other children aged 5 or younger in their household were less likely than pregnant women without other children aged 5 or younger in their household to have misused opioids in the past month (0.6 vs. 1.1 percent, respectively; Figure 3).
Figure 3. Past month opioid misuse among pregnant women aged 15 to 44, by pregnancy trimester and presence of other children aged 5 or younger: 2007 to 2012
Substance Use Treatment Admissions
Although NSDUH data can help define the scope of opioid misuse among pregnant women and identify vulnerable subgroups within the population of pregnant women, TEDS data inform the number of female admissions (pregnant and nonpregnant) who are getting help for opioid misuse, their insurance status, and whether medication-assisted treatment was part of their substance use treatment program. In 2012, TEDS collected data on 428,662 female admissions to substance use treatment who reported that they were aged 15 to 44 at treatment entry; of these, 5.0 percent—21,553 admissions—were pregnant at the time of admission. Pregnant female admissions were aged 26.5 years on average, whereas nonpregnant female admissions aged 15 to 44 were an average age of 29.3 years.
As noted previously, TEDS collects data on the primary substance of misuse and up to two additional substances of misuse reported at the time of admission. In this report, the percentages reflect the misuse of any heroin or nonheroin opioid, whether it be the primary, secondary, or tertiary substance of misuse. Nearly one-quarter (22.9 percent) of pregnant treatment admissions reported any heroin use in 2012, and more than one-quarter (28.1 percent) reported any nonheroin opioid misuse (Figure 4).14 Similar proportions of nonpregnant female admissions reported any heroin use (20.1 percent) or any nonheroin opioid misuse (23.5 percent).
Figure 4. Reported opioid misuse among female admissions aged 15 to 44, by pregnancy status: 2012
Health Insurance Status of Treatment Admissions
More than half (52.5 percent) of pregnant female admissions aged 15 to 44 were covered by Medicaid at the time of treatment entry (Figure 5). Coverage by Medicaid at the time of entry was more common for pregnant women than for nonpregnant women (52.5 vs. 31.9 percent). Nearly one-third (32.7 percent) of pregnant female admissions aged 15 to 44 did not have health insurance, and 4.6 percent reported having some form of private health insurance at the time of treatment entry. Pregnant women were less likely to report lacking health insurance coverage at the time of treatment entry than nonpregnant women (32.7 vs. 48.7 percent) (Figure 5).
Medication-Assisted Opioid Therapy
TEDS collects data on whether medication-assisted opioid therapy was planned as part of a client's treatment program. Medication-assisted opioid therapy within TEDS is defined as opioid therapy using methadone or buprenorphine.9,10 About half of pregnant female admissions aged 15 to 44 who reported heroin use (48.5 percent) had medication-assisted opioid therapy as a part of their treatment plan, compared with fewer than one-quarter (23.4 percent) of nonpregnant female admissions with heroin use (Figure 6). Also, for female admissions aged 15 to 44 who reported nonheroin opioid misuse, a larger proportion of pregnant female admissions had medication-assisted opioid therapy as a part of their treatment plan (36.9 percent) compared with nonpregnant female admissions (15.5 percent).
Figure 5. Health insurance status among female admissions aged 15 to 44, by pregnancy status: 2012
Figure 6. Proportion of female substance use treatment admissions aged 15 to 44 for whom medication-assisted opioid therapy was planned, by pregnancy status and reported opioid substance: 2012
Types of Substance Use Treatment Facilities
Within N-SSATS, outpatient-only, hospital inpatient, and residential treatment facilities11 are asked whether they provide specially designed programs or groups for pregnant/postpartum women. In 2012, 13 percent of outpatient-only substance use treatment facilities and 13 percent of residential treatment facilities offered special programs for pregnant/postpartum women (1,268 outpatient-only treatment facilities and 477 residential treatment facilities; Table 1). Within hospital inpatient treatment facilities, 7 percent, or 52 hospital inpatient treatment facilities, offered special programs for pregnant/postpartum women.
Table 1. Substance use treatment facilities that offered a special program or group for pregnant/postpartum women, by type of treatment facility: 2012
Opioid Treatment Programs and Detoxification Services
Within the N-SSATS data for outpatient-only treatment facilities, residential treatment facilities, and hospital inpatient treatment facilities, three types of opioid-related programs are identified: (1) OTPs offering maintenance and/or detoxification services,12,13 (2) facilities offering opioid detoxification services, and (3) facilities offering buprenorphine-assisted treatment. OTPs are distinguished from other treatment programs because they are certified to use specific opioid drugs such as methadone in treating opioid dependence.9,12,13 Note that although an OTP can offer buprenorphine as part of a treatment program, certified physicians in health care settings outside of OTPs can approve buprenorphine for substance use treatment.9
Of the outpatient-only treatment facilities that offered specially designed programs for pregnant/postpartum women in 2012, 38 percent (487 facilities) operated an OTP, 25 percent (317 facilities) offered opioid detoxification services, and 29 percent (374 facilities) offered buprenorphine services (Figure 7). Of the 8,876 outpatient-only treatment facilities that did not offer specially designed programs for pregnant/postpartum women, 6 percent (539 facilities) operated an OTP, 6 percent (558 facilities) offered opioid detoxification services, and 15 percent (1,302 facilities) offered buprenorphine services (data not shown). Among outpatient-only treatment facilities operating an OTP that also offered specially designed programs for pregnant/postpartum women, more than two-thirds (71 percent) offered both maintenance programs and detoxification12 services, 29 percent offered maintenance programs only, and 1 facility offered detoxification services only. Among outpatient-only treatment facilities operating an OTP that did not offer specially designed programs for pregnant/postpartum women, 58 percent offered both maintenance programs and detoxification services, 41 percent offered maintenance programs only, and 1 percent offered detoxification services only (data not shown).
Figure 7. Substance use treatment facilities that offered special programs or groups for pregnant/postpartum women, by treatment facility type, opioid treatment program (OTP) status, and detoxification and buprenorphine services: 2012
Of the residential treatment facilities that offered specially designed programs for pregnant/postpartum women, 4 percent (21 facilities) operated an OTP, 24 percent (113 facilities) offered opioid detoxification services, and 27 percent (131 facilities) offered buprenorphine services (Figure 7). In comparison, of the 3,089 residential treatment facilities that did not offer specially designed programs for pregnant/postpartum women, 2 percent (60 facilities) operated an OTP, 24 percent (749 facilities) offered opioid detoxification services, and 25 percent (760 facilities) offered buprenorphine services (data not shown). Among residential treatment facilities operating an OTP that also offered specially designed programs for pregnant/postpartum women, 67 percent offered both maintenance programs and detoxification services, 19 percent offered maintenance programs only, and 14 percent offered detoxification services only (data not shown). Among residential treatment facilities operating an OTP that did not offer specially designed programs for pregnant/postpartum women, 50 percent offered both maintenance programs and detoxification services, 18 percent offered maintenance programs only, and 32 percent offered detoxification services only (data not shown).
Of hospital inpatient treatment facilities that offered specially designed programs for pregnant/postpartum women, 17 percent (9 facilities) operated an OTP, 85 percent (44 facilities) offered opioid detoxification services, and 60 percent (31 facilities) offered buprenorphine services (Figure 7). In comparison, of the 728 hospital inpatient treatment facilities that did not offer specially designed programs for pregnant/postpartum women, 10 percent (76 facilities) operated an OTP, 78 percent (565 facilities) offered opioid detoxification services, and 62 percent (454 facilities) offered buprenorphine services (data not shown). Among hospital inpatient treatment facilities operating an OTP that also offered specially designed programs for pregnant/postpartum women, 44 percent offered both maintenance and detoxification services, 11 percent offered maintenance programs only, and 44 percent offered detoxification services only. Among hospital inpatient treatment facilities operating an OTP that did not offer specially designed programs for pregnant/postpartum women, 47 percent offered both maintenance programs and detoxification services, 7 percent offered maintenance programs only, and 46 percent offered detoxification services only (data not shown).
Services for Children
Facilities were asked to identify whether they provided child care services. Overall, child care services were more commonly offered by residential treatment facilities (13 percent) than by outpatient-only or inpatient treatment facilities (6 and 2 percent, respectively; data not shown). This pattern was repeated, but with higher levels of child care services, among facilities with programs for pregnant/postpartum women. Among residential treatment facilities that offered special groups for pregnant/postpartum women in 2012, slightly more than half (54 percent) offered child care services, and 58 percent offered residential beds for children. About 1 in 5 (18 percent) outpatient-only treatment facilities offering special groups or programs for pregnant/postpartum women offered child care services (data not shown). Among hospital inpatient treatment facilities offering special groups or programs for pregnant/postpartum women, 15 percent offered child care services, and 12 percent reported having residential beds for children (data not shown). (Note that a facility may offer more than one type of care; e.g., a hospital inpatient treatment facility may also offer residential care.)
Notably, N-SSATS data indicate that child care services were more frequently provided in residential treatment facilities with specially designed programs for pregnant/postpartum women than in other types of treatment facilities. For example, among residential treatment facilities thatoffered special groups for pregnant/postpartum women, 54 percent offered child care services compared with 6 percent of residential treatment facilities that did not offer special groups for pregnant/postpartum women. Among facilities that did not offer specially designed programs for pregnant/postpartum women, child care services were offered by 6 percent (191 facilities) of residential treatment facilities and 1 percent (10 facilities) of hospital inpatient treatment facilities (data not shown).
Medicaid Coverage
About two-thirds of outpatient-only and residential treatment facilities that offered specially designed programs or groups for pregnant/postpartum women (68 and 61 percent, respectively) accepted Medicaid as a form of payment in 2012. In comparison, 79 percent of hospital inpatient treatment facilities that offered specially designed programs or groups for pregnant/postpartum women accepted Medicaid as a form of payment (data not shown).
Opioid misuse can disrupt fetal development at any stage during a pregnancy—even before a woman knows she is pregnant. In fact, the first months of pregnancy are a time of greater risk of congenital heart defects and other negative neonatal and maternal outcomes.2,3 In this report, 2007 to 2012 NSDUH data show that an annual average of about 21,000 pregnant women misused opioids in the past month. Given the overall dangers of opioid misuse in general and the rise in the number of infants born with opioid dependence,1 outreach and educational resources may help women access needed services to address opioid misuse during pregnancy. Because pregnant women aged 15 to 17 and aged 18 to 25 were more likely than their older counterparts to have misused opioids in the past month, prevention and intervention efforts targeting adolescents and younger women may be especially beneficial.
Poverty is associated with less favorable pregnancy outcomes, such as higher preterm delivery rates.15 NSDUH data also showed that pregnant women living below the federal poverty level were more likely to misuse opioids than pregnant women living at or above the federal poverty level.
Some women who enter treatment may need prenatal or postpartum services and child care assistance postpartum. Fewer pregnant women with children younger than 5 years in their household engaged in opioid misuse than pregnant women without children younger than 5 years in their household. However, increased child care offerings among the nation's opioid and substance use treatment facilities may decrease barriers to treatment for all women with children, particularly for those living below the federal poverty level. N-SSATS data indicate that compared with other types of treatment facilities, residential treatment facilities provided child care services most frequently, regardless of whether they offered specially designed programs for pregnant/postpartum women. Notably, the TEDS analysis showed that a greater proportion of medication-assisted opioid therapy was planned for pregnant female admissions than for other female admissions.9,13
TEDS data showed relatively high health insurance gaps among pregnant substance use treatment admissions, compounding the issue of greater opioid misuse found among pregnant women living below the federal poverty level. Although pregnant female admissions were more likely than other female admissions to have Medicaid coverage and were less likely to be uninsured, nearly one-third of pregnant female admissions reported no health insurance coverage at the time of treatment entry. At the same time, N-SSATS data indicate that between 61 percent (residential treatment facilities) and 79 percent (hospital inpatient treatment facilities) of facilities that offered specialized programs or groups to pregnant or postpartum women accepted Medicaid as a form of payment. The expense of substance use treatment can be a financial barrier for people in need of opioid misuse treatment, and this may be especially daunting for pregnant women and mothers. Assistance in navigating the health insurance and health service opportunities provided by the Affordable Care Act may be especially helpful to pregnant women and adult women of childbearing age.
Access to opioid misuse treatment16 within a continuum of obstetric and medical care is vital for pregnant women.4,5,6,7 In addition to expanded substance use treatment coverage, one of the key reforms of the Affordable Care Act is comprehensive coverage of preventive services for women and young children, including preconception and prenatal care visits. Helping pregnant women who need opioid misuse treatment access these newly available substance use treatment resources as well as expanded prenatal medical care resources may improve health outcomes for mothers and infants. For example, participation in opioid misuse treatment programs could provide pregnant women with improved access to the larger health care system, including obstetric and medical care.
Pregnant women who need assistance with an opioid misuse issue may use the SAMHSA Behavioral Health Treatment Services Locator found at http://findtreatment.samhsa.gov/. For substance use treatment professionals seeking information on the specific substance use treatment needs of adult women of childbearing age, please visit https://store.samhsa.gov/product/TIP-51-Substance-Abuse-Treatment-Addressing-the-Specific-Needs-of-Women/SMA14-4426.
Smith, K. and Lipari, R.N. Women of childbearing age and opioids. The CBHSQ Report: January 17, 2017. Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, Rockville, MD.